Men with Graves' disease who stop taking medication are about two and a half times more likely to experience a return of hyperthyroidism than women, even when their antibody levels are similar.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A meta-analysis of prospective studies could determine whether the male sex association with Graves' relapse is consistent across ethnicities, treatment protocols, and assay methods.
Systematic review and meta-analysis of all prospective cohort studies reporting sex-specific relapse rates after antithyroid drug withdrawal in Graves' disease, with adjustment for age, TSI, TBII, and drug duration. Pooled hazard ratios with subgroup analyses by region and assay type.
An RCT could test whether sex-specific treatment durations reduce relapse in men, establishing whether the association is modifiable.
Multicenter RCT of 400 adults with Graves' disease (200 male, 200 female) randomized to standard (18-month) vs extended (36-month) antithyroid drug therapy, with primary outcome: relapse rate at 5 years stratified by sex.
A prospective cohort could confirm whether male sex independently predicts relapse across diverse populations and confirm the magnitude of risk.
Prospective cohort of 500 adults with Graves' disease starting antithyroid drugs, with sex, age, TSI, TBII, and smoking status recorded at baseline. Follow-up for 5 years to record relapse, with Cox regression adjusting for confounders.
A case-control study could compare hormonal profiles or immune markers between male and female relapsers to identify potential biological mediators.
Case-control study of 100 male and 100 female patients with Graves' disease who relapsed within 2 years, compared to 200 sex-matched non-relapsers, measuring serum estradiol, testosterone, and X-chromosome inactivation patterns.
A cross-sectional study could compare TSI levels at a single time point between men and women with Graves' disease to assess whether sex differences in antibody levels explain relapse risk.
Cross-sectional analysis of TSI and TBII levels in 300 adults with Graves' disease at the time of drug discontinuation, comparing mean levels between men and women, with relapse status recorded retrospectively.